Navigation Links
TGen-led study reveals TWEAK-Fn14 as key drug target
Date:11/8/2013

PHOENIX, Ariz. Nov. 8, 2013 A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute (TGen).

TWEAK is a cytokine, or soluble protein, that controls many cellular activities and acts by binding to a cell surface receptor known as Fn14. TWEAK binding to Fn14 triggers a wide range of cellular activities, including blood clotting, inflammation, cell proliferation, cell migration, and the creation of new blood vessels.

While many of these activities are beneficial for example, helping to heal a cut excessive TWEAK-Fn14 activation also has been linked to tissue damage and degradation, including autoimmune diseases, as well as the survival, migration and invasion of cancer cells.

"Our results show that the TWEAK-Fn14 interaction is a viable drug target, and they provide the foundation for further exploration of this system in researching invasive cancers," said Dr. Nhan Tran, an Associate Professor in TGen's Cancer and Cell Biology Division.

"Because of its unique qualities and association with acute injuries, this drug-like molecule not only could benefit cancer patients, but also might be applied to patients with autoimmunity, heart disease like atherosclerosis, and rheumatoid arthritis," said Dr. Tran, the study's senior author.

The study Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-Inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis publishes in today's (Nov. 8) issue of The Journal of Biological Chemistry.

Overexpression of TWEAK-Fn14 has been linked to several types of cancer, including breast, pancreatic, esophageal, lung, liver and most important in this study glioblastoma.

By using protein-protein docking models, 129 small molecules were selected for screening, which identified four that inhibited the binding of TWEAK to Fn14.

One compound in particular, L524-0366, "completely suppressed TWEAK induced glioma cell migration without any potential cytotoxic effects," the study concluded.

"These results represent a significant step towards proving that the TWEAK-Fn14 interaction may be key to treating invasive glioblastoma brain tumors," said Dr. Michael Berens, TGen Deputy Director for Research Resources and Director of TGen's Cancer and Cell Biology Division.

"The next step will be to move this compound forward for drug development and eventual testing in clinical trials, where it might bring immediate benefit for patients," said Dr. Berens, a co-author of the study.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen-led study identifies genes associated with unhealthy liver function
2. Study using stem cells to improve organ transplantation to receive $12 million
3. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
4. Study finds that Americans want doctors guidance on genetic test results
5. New study assesses injuries seen in the emergency department to children of teenage parents
6. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
7. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
8. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
9. Physician shortage could be cut by new primary care models, study finds
10. Study: Access to health care increases prescription opioid availability and associated abuse
11. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2020)... ... , ... United Security Health and Casualty Insurance Company (United Security) ... in the state of Oklahoma. Lisa Cordero, COO, United Security began, “A Short Term ... all financial situations. STMM can be a bridge, providing comprehensive health coverage, until the ...
(Date:4/5/2020)... ... April 05, 2020 , ... In the midst of crisis, ... Nufabrx®, a proprietary biomaterial company that seamlessly embeds active ingredients including vitamins, supplements ... has shifted production for a new line of reusable copper medical masks called ...
(Date:4/2/2020)... (PRWEB) , ... April 02, 2020 , ... LifeLearn ... VetFolio , today announced the launch of the veterinary CE course COVID-19: What ... indefinitely for VetFolio subscribers. , “When it comes to COVID-19, it’s important for practices ...
(Date:4/2/2020)... ... April 02, 2020 , ... Representatives fighting for ... their parents, grandparents, and guardians, to file a proof of claim in order ... will be made available by Purdue as part of its bankruptcy settlement. , ...
(Date:4/1/2020)... ... ... According to data released by Power to Decide , an estimated ... live in counties impacted by the implementation of the Title X Family Planning Program ... their Title X resources. , The domestic gag rule requires health providers ...
Breaking Medicine News(10 mins):
(Date:4/7/2020)... ... April 07, 2020 , ... Ziegler, a ... (PHC) on its investment by Council Capital (Council). PHC is the leading provider ... current footprint in surrounding states. PHC will use this investment to fund its ...
(Date:4/7/2020)... RATON, Fla. (PRWEB) , ... April 07, 2020 , ... ... Emergent Care , The Coronavirus pandemic means health care providers are adopting radical precautions ... Center has ceased all procedures except those of an urgent or emergency nature. Brent ...
(Date:4/5/2020)... ... April 05, 2020 , ... INTRODUCTION , As the world’s ... of COVID-19[1], we are committed to the non-profit dissemination of our COVID-19 discoveries ... post-entry suppression of ACE2 mRNA expression in host cells is one of our ...
Breaking Medicine Technology: